Kura Oncology, Inc. (KURA) NASDAQ

6.52

+0.025(+0.39%)

Updated at May 02 03:51PM

Currency In USD

Kura Oncology, Inc.

Address

12730 High Bluff Drive

San Diego, CA 92130

United States of America

Phone

858 500 8800

Sector

Healthcare

Industry

Biotechnology

Employees

192

First IPO Date

September 16, 2015

Key Executives

NameTitlePayYear Born
Dr. Troy Edward Wilson J.D., Ph.D.Chairman, Chief Executive Officer & President1.3M1969
Ms. Teresa Brophy Bair Esq., J.D.Chief Legal Officer & Corporate Secretary745,0211971
Ms. Kathleen FordChief Operating Officer868,9351947
Dr. Roger Bakale Ph.D.Senior Vice President of Manufacturing & Supply Chain0N/A
Dr. Mollie Leoni M.D.Chief Medical Officer01978
Dr. Francis J. Burrows Ph.D.Chief Scientific Officer01962
Ms. Maureen Clancy M.B.A.Vice President and Global Head of Program Leadership & Project Management0N/A
Mr. Brian T. Powl M.B.A., M.S.Chief Commercial Officer01974
Mr. Thomas DoyleSenior Vice President of Finance & Accounting01971

Description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.